M. Belhassan

Evolution in clinical presentation of inflammatory bowel disease over time at diagnosis: a multicenter cohort study

T. Ramtohul, S. Nahon, V. Abitbol, 2018, European journal of gastroenterology & hepatology.

Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.

A. Amiot, J. Farcet, A. Hulin, 2016, Clinics and research in hepatology and gastroenterology.

Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.

A. Amiot, S. Bastuji‐Garin, F. Mesli, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Maladie d’Alström

I. Errabih, H. Ouazzani, H. Krami, 2009 .

[Alstrom syndrome].

I. Errabih, H. Ouazzani, H. Krami, 2009, Gastroenterologie clinique et biologique.

Giant Trichobezoar of Duodenojejunal Flexure: A Rare Entity

M. Soufi, B. Chad, Rahal Massrouri, 2010, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

Infliximab infusion time in patients with inflammatory bowel diseases: is longer really safer?

A. Amiot, I. Sobhani, J. Lefèvre, 2013, Clinics and research in hepatology and gastroenterology.